These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 17876341

  • 21. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M, Wachter J, Ponholzer A, Leitha T, Rauchenwald M, Madersbacher S.
    Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
    [Abstract] [Full Text] [Related]

  • 22. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?
    Etzioni R, Falcon S, Gann PH, Kooperberg CL, Penson DF, Stampfer MJ.
    Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1640-5. PubMed ID: 15466981
    [Abstract] [Full Text] [Related]

  • 23. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
    Kobayashi T, Kamoto T, Nishizawa K, Mitsumori K, Ogura K, Ide Y.
    BJU Int; 2005 Apr; 95(6):761-5. PubMed ID: 15794778
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Serum levels of hepatocyte growth factor in patients with breast cancer.
    Sheen-Chen SM, Liu YW, Eng HL, Chou FF.
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
    [Abstract] [Full Text] [Related]

  • 29. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
    Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC.
    J Urol; 1999 Jan; 161(1):182-7. PubMed ID: 10037394
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Does PSA velocity predict prostate cancer in pre-screened populations?
    Schröder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH.
    Eur Urol; 2006 Mar; 49(3):460-5; discussion 465. PubMed ID: 16442212
    [Abstract] [Full Text] [Related]

  • 33. Transforming growth factor-beta1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia.
    Wolff JM, Fandel T, Borchers H, Brehmer B, Jakse G.
    Br J Urol; 1998 Mar; 81(3):403-5. PubMed ID: 9523660
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J, Haese A, Scattoni V, Steuber T, Chun FK, Briganti A, Montorsi F, Graefen M, Huland H, Karakiewicz PI.
    Cancer; 2008 Nov 15; 113(10):2695-703. PubMed ID: 18853417
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels.
    Tanaka N, Fujimoto K, Chihara Y, Torimoto M, Hirao Y, Konishi N, Saito I.
    Prostate Cancer Prostatic Dis; 2007 Nov 15; 10(3):274-8. PubMed ID: 17339878
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.